You are not currently logged in.
Access JSTOR through your library or other institution:
A Response to Strategy #2: Streamlining the Regulatory Process
W. Paul Glezen
Clinical Infectious Diseases
Vol. 42, Supplement 3. Strengthening the Supply of Routinely Administered Vaccines in the United States: Presentations at Workshops Convened by the National Vaccine Advisory Committee, Department of Health and Human Services, February 2002 and January 2005 (Mar. 1, 2006), pp. S141-S144
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4463699
Page Count: 4
You can always find the topics here!Topics: Vaccination, Influenza, Orthomyxoviridae, Drug regulation, Disease risk, Dosage, Government regulation, Immunization, Medical practice, Creutzfeldt Jakob syndrome
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Regulatory burden has contributed to the decline in the production of vaccines in the United States. Production of influenza virus vaccine is perilously limited at a critical period when vulnerable populations are increasing and the threat of a pandemic is looming. Regulatory bodies must work with manufacturers to facilitate implementation of new production practices, to ensure steady expansion of the supply of safe and effective vaccines.
Clinical Infectious Diseases © 2006 Oxford University Press